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ABSTRACT
Introduction: Patient-reported outcome measures (PROs) exist for psoriasis but not genital
psoriasis (GenPs).
Methods: This cross-sectional, qualitative study
in patients with moderate-to-severe GenPs was
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conducted to support development of a PRO for
measuring the impact of GenPs on sexual
activity and to establish content validity. The
impacts of GenPs were identified in a literature
review. Findings from the literature review were
discussed with clinicians, and then patients
with GenPs were interviewed.
Results: From the literature review, 52 articles,
44 abstracts, and 41 clinical trials met predefined search criteria. Of these, 11 concepts
emerged as having theoretical support for use as
measurable impacts of psoriasis symptoms on
patients; these concepts included sexual functioning and general health-related quality of life
(HRQoL). These concepts were confirmed and
expanded upon by two clinicians who routinely
care for patients with GenPs. Interviews were
then conducted with GenPs patients (n = 20) to
discuss the impact of GenPs on their HRQoL.
Eighty percent of patients reported that GenPs
impacted sexual frequency. The two-item GenPs
Sexual Frequency Questionnaire (GenPs-SFQ)
was developed to assess limitations on sexual
activity frequency because of GenPs. Cognitive
debriefing with an additional 50 patients with
GenPs confirmed the utility and understandability of the GenPs-SFQ.
Conclusion: The GenPs-SFQ may have utility in
clinical trials involving GenPs patients and in
routine clinical practice.
Funding: Eli Lilly and Company.
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Plain Language Summary: Plain
summary available for this article.

language

Keywords: Genital psoriasis; Patient-reported
outcomes; Psoriasis; Quality of life

PLAIN LANGUAGE SUMMARY
Psoriasis is a disease that causes people to have
raised red patches of skin. Psoriasis can cover any
part of the body, may be very itchy, and can
sometimes bleed. Psoriasis currently cannot be
cured, but medicines can make the raised red
patches of skin smaller or completely go away.
Many patients with psoriasis have raised red patches of skin on their genital area. These raised red
patches of skin may itch and bleed, so many of
these patients do not have sex or have sex less
often than they would if they did not have raised
red patches of skin on their genital area. Many
patients find talking about this kind of psoriasis
very difficult, even with their doctor. On the basis
of research and talking with doctors and these
patients, we have developed two questions for use
in doctors’ offices and during clinical studies that
measure the effects of psoriasis on the genital area,
specifically on how often these patients engage in
sexual activity and how often their genital psoriasis causes them to avoid sexual activity. Patients
may answer these questions before, during, and
after taking medicine to treat psoriasis on their
genital area. The answers to these questions may
help doctors learn how well certain medicines
work for psoriasis that affects the genital area.

INTRODUCTION
At some point during the course of their disease,
up to 63% of patients with chronic plaque psoriasis have psoriatic lesions in the genital area [1–3].
Sexual impairment and pruritus are major issues
for patients with genital psoriasis (GenPs) [3–5].
Health-related quality of life (HRQoL) is significantly worse in psoriasis patients with genital
involvement compared with those without, even
after correcting for overall psoriasis severity [3, 4].
GenPs has a significant impact on sexual
health [3, 4, 6, 7]. Women with psoriasis in the

genital region have especially high levels of
sexual distress [4]. Compared with patients
without genital involvement, those with genital
involvement experience a significantly higher
impact on sexual function, sexual frequency,
and fear of sexual relations [3]. Although GenPs
significantly impacts HRQoL and sexual health,
many health care professionals do not routinely
question patients about or examine them for
this condition [8, 9]. Likewise, patients frequently do not discuss genital involvement
with health care providers [8, 10, 11].
Although GenPs has a substantial impact on
patient well-being and HRQoL, the effect of
therapy on psoriasis in the genital region has
been tested in only a few open-label clinical
trials [12–14]. Numerous patient-reported outcome measures (PROs) are available for measuring symptoms and the impact of overall
psoriasis on HRQoL [15, 16], but none are
specific to GenPs. However, a few PROs related
to sexual health have been used to assess sexual
health in a study involving patients with GenPs
[4]: the Female Sexual Function Index [17, 18],
the International Index of Erectile Function
[19], the Female Sexual Distress Scale [18, 20],
and the Sexual Quality of Life Questionnaire for
use in Men [21]; in addition, patients were asked
whether ‘‘they believe that since the onset of
psoriasis sexual activity has declined’’ [4, 6].
The purpose of this study is to report the
development and content validation of a PRO
that measures the impact of GenPs on sexual
health. This instrument—the Genital Psoriasis
Sexual Frequency Questionnaire (GenPs-SFQ)—
has the potential to be a clinically meaningful
standard assessment tool in routine clinical
practice and in clinical trials involving patients
with GenPs.

METHODS
Study Objectives and Design
This was a cross-sectional study designed to
support development and content validity of a
new PRO in GenPs patients. A five-step study
design was employed: (a) literature review to
document the impact of GenPs on sexual
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activity and to identify concepts of GenPs,
(b) clinician input to confirm the concepts of
GenPs that are of greatest clinical relevance to
patients, (c) concept elicitation interviews with
GenPs patients, (d) item generation, and
(e) cognitive debriefing evaluation.
Literature Review
A targeted literature search was conducted to
identify peer-reviewed articles and conference
proceedings that discussed GenPs and its impact
on HRQoL and sexual health. English-language
articles published between 2005 and 2015 or
conference abstracts published between 2011
and 2015 and indexed in EMBASE/Medline were
included (see Table S1 in the supplementary
material for search terms). A separate search of
www.clinicaltrials.gov was performed to identify PROs used in future or active clinical trials
between 2013 and 2015.
Clinician Input
After completion of the literature review, two
USA-based dermatologists were interviewed
including one author of this manuscript (CR);
these clinicians had extensive experience in
treating GenPs and experience in clinical trials
involving psoriasis patients. The interviews’
purpose was to confirm the GenPs impacts most
relevant to patients from the clinician’s
perspective.
Concept Elucidation
Participants were recruited in the USA from five
clinical sites located in Arkansas, Indiana,
Michigan, and Washington. Participants were
eligible if, at screening, they were aged at least
18 years and had confirmed chronic plaque
psoriasis for at least 6 months, had an affected
body surface area of at least 1%, and had a
current or recent history (within 3 months) of
moderate or severe genital involvement (Patient
Global Assessment score C 4 on a 6-point scale
from 0 to 5) as reported by the patient and
confirmed by the site investigator. Participants
were eligible if they failed to respond to or had

35

been intolerant of one or more topical therapies
for GenPs.
One-on-one participant interviews were
planned as in-person or telephone interviews
using a semistructured guide. Interviews were
audio-recorded and transcribed, and the transcripts were de-identified. Interviews were conducted between August 19, 2015, and
November 19, 2015. All procedures followed
were in accordance with the ethical standards of
the responsible committee on human experimentation (institutional and national) and with
the Helsinki Declaration of 1964, as revised in
2013. Written and verbal informed consent for
audio recording was obtained from all participants for being included in the study, although
the study was determined to be ‘‘exempt’’ by the
local institutional review board (Chesapeake
IRB, Columbia, MD, USA). Before the telephone
interviews were conducted, packets containing
the informed consent form and study materials
were mailed to participants.
Concept elicitation was performed during
the interviews. Participants were asked
open-ended questions without any definitions
of symptoms or impacts and were then questioned on predefined symptoms and impacts.
Each participant’s interview was completed in
one session lasting approximately 2 h. Upon
completion, participants were remunerated for
their time.
Item Generation
The findings of the literature review, clinician
review, and concept elicitation identified and
confirmed that decrements in sexual function
were an important impact of GenPs. This
strongly supported the development of a new
PRO instrument, the GenPs-SFQ, to measure the
impact of GenPs on sexual frequency for use in
trials evaluating treatments for GenPs. Two
global items were generated on the basis of how
patients described their experience: the first
addressed the frequency of sexual activity over
the previous week, and the second addressed
how often GenPs limited the frequency of sexual activity during the same week.
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Response options for each item were
designed so that the full range of frequency was
captured, reflecting what had been learned
through concept elicitation; in practice,
responses can be captured in the format of a
weekly diary. The recall period of 1 week and
weekly diary approach were selected to best
capture the frequency of sexual activity and the
patient’s ability to recall it accurately as guided
by results of the concept elicitation interviews.
Cognitive Debriefing
Cognitive debriefing interviews to confirm item
comprehension and appropriateness of the final
GenPs-SFQ were conducted with a second set of
50 participants from seven countries and one
US territory (Australia, Austria, Belgium,
Canada, Netherlands, Puerto Rico, USA, and
Turkey). The newly developed instrument was
tested on these adults with self-reported GenPs
to ensure that each item of the GenPs-SFQ
adequately captured the concepts as intended
in English for the non-English-speaking countries and to confirm item comprehension and
cultural appropriateness. Before the interviews,
participants were asked to review the GenPsSFQ and circle any words, phrases, or sentences
that were difficult to understand. During the
interviews, participants were asked to identify
any words or phrases they had previously circled. The interviewers then guided subjects
through the documents, line-by-line, asking
them to paraphrase each item. If a subject
expressed difficulty understanding an item or
concept, the interviewers probed to determine
the reason and then elicited suggestions for
rewording the difficult text.

Data Analysis
Qualitative data were based on interview notes,
recordings, and transcripts and were analyzed
using a content analysis approach. Participant
interview transcripts during the concept elicitation phase were analyzed using ATLAS.ti version 7.5.9 (Scientific Software Development
GmbH, Berlin, Germany), which systematically

identified themes within qualitative data. A
coding dictionary based on the semistructured
interview guide was developed. Results from the
debriefing were qualitatively analyzed to determine if changes were necessary to improve the
comprehensibility and relevancy of each GenPsSFQ item.

RESULTS
Literature Review and Clinician Input
Fifty-two articles, 44 abstracts, and 41 clinical
trials met predefined search criteria.
From the literature search, 11 concepts
emerged as having theoretical support for use as
measureable impacts of psoriasis symptoms on
HRQoL or sexual function (Table 1). The most
frequent concepts overall were psychological
feelings (n = 42, 80.8%), social relationships
(n = 37, 71.2%), physical activities or general
physical functioning (n = 31, 59.6%), daily living and activities (n = 29, 55.8%), general
HRQoL (n = 29, 55.8%), and work or school
impact (n = 26, 50.0%). Sexual functioning was
discussed by 19 (36.5%) reviewed articles; of
these, 3 (5.8%) articles discussed this concept in
relation to GenPs, making it the most frequently discussed concept specific to GenPs. A
further targeted search of sexual function concepts was conducted by reviewing relevant
conference abstracts (Table 2). Results revealed
the following most frequently emergent concepts: dyspareunia (n = 2, 4.5%), increased discomfort or worsening of symptoms after sex
(n = 2, 4.5%), and sexual dysfunction (n = 2,
4.5%).
During the clinician interviews, sexual
function, which encompasses sexual activity,
was identified as the most relevant functional
impact of GenPs. One clinician emphasized the
difference between sexual activity and sexual
dysfunction (i.e., erectile dysfunction), indicating that GenPs impacts sexual activity, not
sexual dysfunction. Specific impacts on sexual
activity included fear of and avoidance of sex,
pain during sexual intercourse (dyspareunia),
worsening of psoriasis after intercourse, and
bleeding and cracking in the genital area.
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Table 1 Summary of health-related quality of life and/or functional impact concept emergence: published articles (n = 52)
HRQoL/functional concepts

Frequency of mention, n (%)
Total

In relation to
psoriasisa

In relation to
genital psoriasisb

In relation to both
psoriasis and genital
psoriasisc

Psychological feelings (e.g., mood
disturbance)

42 (80.8)

41 (78.8)

1 (1.9)

0 (0)

Social relationships (including social
stigmatization)

37 (71.2)

35 (67.3)

2 (3.8)

0 (0)

Physical activities or general physical
functioning

31 (59.6)

30 (57.7)

1 (1.9)

0 (0)

Daily living and activities

29 (55.8)

28 (53.8)

1 (1.9)

0 (0)

HRQoL

29 (55.8)

28 (53.8)

1 (1.9)

0 (0)

Work or school

26 (50.0)

25 (48.1)

1 (1.9)

0 (0)

Recreation

20 (38.5)

19 (36.5)

1 (1.9)

0 (0)

Sexual functioning

19 (36.5)

15 (28.8)

3 (5.8)

1 (1.9)

Vitality

7 (13.5)

7 (13.5)

0 (0)

0 (0)

Financial

4 (7.7)

4 (7.7)

0 (0)

0 (0)

Cognitive functioning

1 (1.9)

1 (1.9)

0 (0)

0 (0)

Fifty-two articles met the inclusion criteria, but only a subset explicitly discussed health-related quality of life and/or
functional impact concept emergence
HRQoL Health-related quality of life
a
Articles that discussed symptoms in the context of psoriasis in general
b
Articles that discussed symptoms speciﬁcally in the context of genital psoriasis
c
Articles that discussed symptoms in the context of both psoriasis in general and speciﬁcally for genital psoriasis

Avoidance of sex was noted by one clinician as
more commonly mentioned by female patients
as opposed to male patients. Psychological
impacts of GenPs, such as depression and anxiety, were also mentioned by one clinician as
affecting patients. One clinician noted the
impact of sexual activity impairment on the
patient’s partner. A clinician recommended
developing an instrument to assess the impact
of GenPs on sexual health and HRQoL.
Concept Elicitation Interviews
Twenty-two of 25 screened participants met the
study criteria. Two eligible participants were

unavailable; therefore, 20 participants were
interviewed. The mean age of participants was
45 ± 14.2 years (range 21–68); 45% were male,
and 90% were white (Table 3). All participants
chose telephone interviews rather than in-person interviews.
At the beginning of the interview, GenPs was
defined as psoriasis occurring on the ‘‘outer lip’’
(labia majora), ‘‘inner lip’’ (labia minora), and
‘‘area between the vagina and the anus’’ (perineum) for females and on the penis, scrotum,
and ‘‘area between the penis and the anus’’
(perineum) for males. During the patient interviews, sexual functioning was the most common spontaneously endorsed impact of GenPs,
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Table 2 Summary of sexual function concepts: conference proceedings (n = 44)
Sexual function concepts

Frequency of mention, n (%)
In relation to
genital psoriasisb

In relation to both psoriasis and
genital psoriasisc

1 (2.3)

0 (0)

Increased discomfort/worsening of 2 (4.5) 0 (0)
symptoms after sex

2 (4.5)

0 (0)

Sexual dysfunction

2 (4.5) 1 (2.3)

0 (0)

1 (2.3)

Bleeding during sex

1 (2.3) 1 (2.3)

0 (0)

0 (0)

Difﬁculty moving during sex

1 (2.3) 1 (2.3)

0 (0)

0 (0)

Ripping of skin during sex

1 (2.3) 1 (2.3)

0 (0)

0 (0)

Vaginal dryness

1 (2.3) 1 (2.3)

0 (0)

0 (0)

Total
Dyspareunia

In relation to
psoriasisa

2 (4.5) 1 (2.3)

Forty-four conference proceedings met the inclusion criteria, but only a subset explicitly discussed sexual function concepts
a
Conference proceedings that discussed symptoms in the context of psoriasis in general
b
Conference proceedings that discussed symptoms speciﬁcally in the context of genital psoriasis
c
Conference proceedings that discussed symptoms in the context of both psoriasis in general and speciﬁcally for genital
psoriasis

with 18 (90%) participants spontaneously
endorsing one or more aspects of sexual impact.
When asked about impact of GenPs on sexual
activity (defined as not limited to intercourse
and including activities such as masturbation),
the most common impacts of GenPs were on
sexual frequency, sexual experience, and
symptom worsening after sexual activity, each
reported by 80% of participants. Table 4 shows
other impacts of GenPs on sexual activity. Upon
reviewing the transcripts of the patient interviews, reduced sexual frequency and avoidance
of sexual activity and/or intimate relationships
because of physical symptoms or embarrassment were common themes. Table 5 shows
representative participant responses. Because of
the non-complex concepts of interest, saturation was achieved with the 20 participants (data
not shown).
Development of GenPs-SFQ
On the basis of the key experiences from the
participant interviews, avoidance of sexual

activity with a subsequent impact on frequency
of sexual activity was a key theme. The two-item
GenPs-SFQ was created to add frequency to the
concept of avoidance of sexual activity
(Table 6). The GenPs-SFQ provides quantification of the impact of GenPs on frequency and
limitations of sexual activity and focuses
specifically on the impact of GenPs on sexual
frequency/activity on the basis of the patient’s
response to item 1 (‘‘In the past week, how
many times did you engage in sexual activity?’’).
This in combination with item 2 (‘‘In the past
week, how often did your genital psoriasis limit
the frequency of your sexual activity?’’) distinguishes between patients who avoid sexual
activity because of GenPs versus reasons unrelated to GenPs. The GenPs-SFQ defines the
genital area as the labia majora (outer lips), labia
minora (inner lips), and perineum (area
between vagina and anus) for females and the
penis, scrotum, and perineum (area between the
penis and anus) for males. The recall period is
1 week.
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Table 3 Patient demographics
Characteristics

Number of patients
responding

n (%) or mean (SD)

Age, years [mean (SD)]

20

45 (14.2)

Sex, n (%)

20

Male
Female
Race, n (%)

–

9 (45)

–

11 (55)

20

White

–

18 (90)

Black or African-American

–

1 (5)

Two or more races

–

1 (5)

Duration of psoriasis, years [mean (SD)]

19

18 (14)

Duration of genital psoriasis, years [mean (SD)]

20

7.5 (9.7)

BSA score, mean (SD)

15

10.4 (12.7)

Self-reported general health within past week, n (%)

20

–

Excellent

–

2 (10)

Very good

–

4 (20)

Good

–

11 (55)

Fair

–

3 (15)

Poor

–

Self-reported severity of overall psoriasis symptoms (worst over past 3 months), n (%) 20

0
–

0 (clear)

–

0

1

–

1 (5)

2

–

1 (5)

3

–

5 (25)

4

–

5 (25)

5 (severe)

–

8 (40)

20

–

0 (clear)

–

0

1

–

0

Self-reported severity of genital psoriasis symptoms (worst over past 3 months), n
(%)a

2
3

1 (5)
–

4
5 (severe)
Sexual activity status, n (%)
Not active

5 (25)
8 (40)

–

6 (30)

20

–

–

9 (45)

Active

–

9 (45)

Not askedb

–

2 (10)

20

14 (70)

Currently receiving treatment for overall psoriasis, n (%)

BSA body surface area
a
All participants met eligibility criteria (Patient Global Assessment C 4, 6-point scale from 0 to 5) at time of screening; the table reﬂects
responses at the time of the interview
b
The question was not asked because of conversation ﬂow, auditory cues, and subject’s apparent lack of comfort with sensitive topics per
interviewer judgment
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Table 4 Functional impact concepts emerging from patient interviews
Sexual impact concepts

Frequency of mention, n (%)
Total

Spontaneous

After probing

Decreased sexual frequency

16 (80)

7 (35)

9 (45)

Worsening of genital psoriasis symptoms after sexual activity

16 (80)

12 (60)

4 (20)

Negative effects on sexual experience

16 (80)

13 (65)

3 (15)

Avoidance of sexual relationships

15 (75)

12 (60)

3 (15)

Reduced sexual desire

11 (55)

2 (10)

9 (45)

n number of patients

Table 5 Patient-reported impacts of genital psoriasis on sexual frequency and avoidance
Representative patient quotations
Decreased sexual frequency
It’s decreased it a lot
I haven’t had sex in about 5 months
Well, you know, you, there’s no sex life
I’m not as sexually active now as when I was, you know, 25 or 21, but so it, it’s, it has gotten to the point you just don’t
have relations
I would say it’s easily cut my frequency down in half
It’s, it’s taken it away just because, I mean, it’s just too painful
No, I, it doesn’t, unless, unless there’s an injury. That’s the only time I’m kind of apprehensive about it
Yeah, so I don’t do it much…. Not very often. It really affects that, trust me
Avoidance of sexual relationships
Well, you know, it’s just another factor that you have in your mind that you really wouldn’t want to expose that to
anyone or have to explain it or have them question you. So you’d rather just skip the whole thing… It probably weighs
on the side of I’m not looking for anybody
No, not currently right now because it kind of comes and goes in stages. I have been off and on but there’s deﬁnitely a lot
of stress because you don’t know if it’s going to ﬂare up that week or next week or when and it’s just a lot to deal with.
There’s not many girls that would be too understanding of what’s going on. Most people think it’s cracking and dry
skin and not a lot of people understand psoriasis so they would think, you know, STD or this or that or what’s wrong
with you or something. So it’s just I’ve steered away from it, I guess, a little bit
Semistructured interviews were conducted with 20 patients. Some patient quotes were edited to minimize redundant
language
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Table 6 Genital psoriasis sexual frequency questionnaire (GenPs-SFQ)
Please answer the questions based on your psoriasis symptoms in the genital areaa within the past Response
week
options
In the past week, how many times did you engage in sexual activityb?

None/zero
Once
Two or more
b

In the past week, how often did your genital psoriasis limit the frequency of your sexual activity ?

Always
Often
Sometimes
Rarely
Never

For permission to reproduce or use the GenPs-SFQ, please contact copyright@lilly.com
Genital area is deﬁned as the labia majora (outer lips), labia minora (inner lips), and perineum (area between vagina and
anus) for females and the penis, scrotum, and perineum (area between the penis and anus) for males
b
Not limited to sexual intercourse and includes activities such as masturbation
a

Cognitive Debriefing
Cognitive debriefing was conducted with 50
participants with an average
age of
47.5 ± 14.6 years (range 18–82) and an average
of 13 ± 3.8 years of academic education (range
6–23 years). Forty-four percent of participants
were male. Patients did not report difficulties
interpreting or using the GenPs-SFQ items, so
no changes were made after the cognitive
debriefing. Overall, the cognitive interviews
revealed that the instructions and items of the
GenPs-SFQ adequately capture the concepts as
intended and were, overall, easily understood in
English and other languages and confirmed as
culturally appropriate by patients with GenPs
residing in the seven countries and one US territory that will be included in the planned
clinical trials.
No participant indicated difficulty in making
a rating using the frequency rating scales. Participants used lower ratings on the scale to
indicate less frequent sexual activity for item 1
and/or less limitation of sexual activity because
of GenPs for item 2. Higher ratings were used to
describe more frequent sexual activity and/or

more limitation in sexual activity because of
GenPs, respectively. Participants thought the
recall period of 1 week was appropriate, made
sense, and was relevant. Participants were able
to make ratings based strictly on this recall
period and reported no difficulty in remembering their experiences over that period.

DISCUSSION
Although multiple PROs exist for measuring the
impact of general psoriasis on HRQoL [15, 16]
and for measuring sexual function [22], none
had been developed or validated specifically for
use with GenPs. Using the concept of sexual
activity avoidance, the GenPs-SFQ was developed specifically for individuals with GenPs.
However, the broader concept of sexual activity
impacts in other psoriasis populations has been
reported. In a survey of 481 Dutch patients with
psoriasis, including patients with genital lesions
at the time of the survey, 24.9% (32.8% of
females; 19.1% of males) reported that sexual
activity declined after the onset of psoriasis [4].
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The GenPs-SFQ measures the impact of
GenPs on patients’ lives in terms of frequency of
sexual activity. Although the GenPs was developed de novo, item 2 (‘‘In the past week, how
often did your genital psoriasis limit the frequency of your sexual activity?’’) does have
some similarity to item 9 of the Dermatology
Life Quality Index (‘‘Over the last week, how
much has your skin caused any sexual difficulties?’’) [23]. These items are easy to understand,
and the GenPs-SFQ can be administered to
patients either on paper or electronically. The
scale is specific to GenPs and is potentially
useful in both clinical trials and routine clinical
practice. The work described here establishes
content validity, which is an initial step in the
development of a new PRO [24–26]. The development of the initial items and participant
interviews were conducted in accordance with
guidelines and best practices for validating
content [24–26].
There may be limitations in the extent to
which these findings can be generalized to all
GenPs patients. The sample size (N = 20)
appears small, but saturation, which is the point
whereby gathering additional data does not
yield new concepts [27], was reached with 20
patients; saturation is the recommended
method for determining the sample size for
concept elicitation interviews [26]. Racial
minorities were underrepresented in the original sample of 20 patients. Sexual orientation
was not included in the baseline demographic
questions. Notably, all patients chose telephone
interviews over in-person interviews, and this
should be noted for future studies; it is possible
that patients may have been less forthcoming if
in-person interviews had been conducted.
Finally, the described work is qualitative;
therefore, psychometric properties of the
GenPs-SFQ still need to be evaluated to determine the instrument’s reliability, validity, and
ability to measure changes in patient wellbeing.

CONCLUSIONS
The GenPs-SFQ may help obtain information
that is relevant to understanding the burden of
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genital psoriasis and inform potential treatment
in both clinical and research settings. Practitioners should consider ways to make patients
feel more comfortable discussing their GenPs.
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